α-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: A multicenter randomized controlled (MACS) study

Cardiovascular Diabetology

Volumn 16, Issue 1, 2017, Pages

  Shimabukuro, Michio ^a,b   Tanaka, Atsushi ^c   Sata, Masataka ^b   Dai, Kazuoki ^d   Shibata, Yoshisato ^e   Inoue, Yohei ^c,e   Ikenaga, Hiroki ^d   Kishimoto, Shinji ^d   Ogasawara, Kozue ^b   Takashima, Akira ^b   Niki, Toshiyuki ^b   Arasaki, Osamu ^f   Oshiro, Koichi ^g   Mori, Yutaka ^h   Ishihara, Masaharu ⁱ   Node, Koichi ^c  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c SAGA UNIVERSITY   (Japan)

^d HIROSHIMA CITY HOSPITAL   (Japan)

^e Miyazaki Medical Association Hospital   (Japan)

^f Tomishiro Central Hospital   (Japan)

^g Ohama Hospital II   (Japan)

^h JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Acute coronary syndrome; Glucose fluctuation; Heart rate variability; Hypoglycemia; Miglitol; Sympathetic nervous system activity; Type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE; BISOPROLOL; CARVEDILOL; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; METFORMIN; MIGLITOL; PIOGLITAZONE; 1 DEOXYNOJIRIMYCIN; ANTIDIABETIC AGENT; GLYCOSIDASE INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART RATE VARIABILITY; HOLTER MONITORING; HUMAN; HYPOGLYCEMIA; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PARALLEL DESIGN; PILOT STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYMPATHETIC TONE; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; CLINICAL TRIAL; DRUG EFFECTS; HEART RATE; MIDDLE AGED; TREATMENT OUTCOME;

1-DEOXYNOJIRIMYCIN; ACUTE CORONARY SYNDROME; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE; GLYCOSIDE HYDROLASE INHIBITORS; HEART RATE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 85022075532     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-017-0571-1     Document Type: Article

References (31)

1. Kosiborod M, Rathore SS, Inzucchi SE, Masoudi FA, Wang Y, Havranek EP, Krumholz HM. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation. 2005;111:3078-86.
2. Kosiborod M, Inzucchi SE, Krumholz HM, Xiao L, Jones PG, Fiske S, Masoudi FA, Marso SP, Spertus JA. Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation. 2008;117:1018-27.
3. Mellbin LG, Malmberg K, Waldenström A, Wedel H, Rydén L. Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes: a report from the DIGAMI 2 trial. Heart. 2009;95:721-7.
4. Svensson A-M, McGuire DK, Abrahamsson P, Dellborg M. Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J. 2005;26:1255-61.
5. Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013;347:f4533.
6. Lee SA, Cho SJ, Jeong MH, Kim YJ, Kim CJ, Cho MC, Kim HS, Ahn Y, Koh G, Lee JM, et al. Hypoglycemia at admission in patients with acute myocardial infarction predicts a higher 30-day mortality in patients with poorly controlled type 2 diabetes than in well-controlled patients. Diabetes Care. 2014;37:2366-73.
7. Reno CM, Daphna-Iken D, Chen YS, VanderWeele J, Jethi K, Fisher SJ. Severe hypoglycemia-induced lethal cardiac arrhythmias are mediated by sympathoadrenal activation. Diabetes. 2013;62:3570-81.
8. Nordin C. The proarrhythmic effect of hypoglycemia: evidence for increased risk from ischemia and bradycardia. Acta Diabetol. 2014;51:5-14.
9. Chow E, Bernjak A, Williams S. Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes. 2014;63:1738-47.
10. Matsuura K, Mori Y, Nakamura A, Yokoyama J, Utsunomiya K. Effect of miglitol as an add-on to bolus insulin on postprandial glycemic excursions in type 2 diabetes patients assessed by continuous glucose monitoring. Diabetes Technol Ther. 2012;14:423-9.
11. JCS Joint Working Group. Guidelines for rehabilitation in patients with cardiovascular disease (JCS 2012). Circ J. 2014;78:2022-93.
12. Joseph JI, Torjman MC, Strasma PJ. Vascular glucose sensor symposium: continuous glucose monitoring systems (CGMS) for hospitalized and ambulatory patients at risk for hyperglycemia, hypoglycemia, and glycemic variability. J Diabetes Sci Technol. 2015;9:725-38.
13. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes. 1970;19:644-55.
14. Hermanns N, Schumann B, Kulzer B, Haak T. The impact of continuous glucose monitoring on low interstitial glucose values and low blood glucose values assessed by point-of-care blood glucose meters: results of a crossover trial. J Diabetes Sci Technol. 2014;8:516-22.
15. Task Force of the European Society of Cardiology the North American Society of Pacing Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation. 1996;93:1043-65.
16. Jabre P, Roger VL, Weston SA, Adnet F, Jiang R, Vivien B, Empana JP, Jouven X. Resting heart rate in first year survivors of myocardial infarction and long-term mortality: a community study. Mayo Clin Proc. 2014;89:1655-63.
17. Koivikko ML, Salmela PI, Airaksinen KE, Tapanainen JS, Ruokonen A, Mäkikallio TH, Huikuri HV. Effects of sustained insulin-induced hypoglycemia on cardiovascular autonomic regulation in type 1 diabetes. Diabetes. 2005;54:744-50.
18. Kishimoto M, Noda M. A pilot study of the efficacy of miglitol and sitagliptin for type 2diabetes with a continuous glucose monitoring system and incretin-related markers. Cardiovasc Diabetol. 2011;10:115.
19. Li FF, Xu XH, Fu LY, Su XF, Wu JD, Lu CF, Ye L, Ma JH. Influence of acarbose on plasma glucose fluctuations in insulin-treated patients with type 2 diabetes: a pilot study. Int J Endocrinol. 2015;2015:903524.
20. Kitano D, Chiku M, Li Y, Okumura Y, Fukamachi D, Takayama T, Hiro T, Saito S, Hirayama A. Miglitol improves postprandial endothelial dysfunction in patients with acute coronary syndrome and new-onset postprandial hyperglycemia. Cardiovasc Diabetol. 2013;12:92.
21. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004;25:10-6.
22. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486-94.
23. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, Boemi M, Giugliano D. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008;57:1349-54.
24. Smits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Diamant M, van Raalte DH. The effects of GLP-1 based therapies on postprandial haemodynamics: two randomised, placebo-controlled trials in overweight type 2 diabetes patients. Diabetes Res Clin Pract. 2017;124:1-10.
25. Meyer ML, Gotman NM, Soliman EZ, Whitsel EA, Arens R, Cai J, Daviglus ML, Denes P, González HM, Moreiras J, et al. Association of glucose homeostasis measures with heart rate variability among Hispanic/Latino adults without diabetes: the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Cardiovasc Diabetol. 2016;15:45.
26. Saito I, Hitsumoto S, Maruyama K, Nishida W, Eguchi E, Kato T, Kawamura R, Takata Y, Onuma H, Osawa H, et al. Heart rate variability, insulin resistance, and insulin sensitivity in Japanese adults: the toon health study. J Epidemiol. 2015;25:583-91.
27. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J. 1996;17:354-81.
28. Kurajoh M, Koyama H, Kadoya M, Naka M, Miyoshi A, Kanzaki A, Kakutani-Hatayama M, Okazaki H, Shoji T, Moriwaki Y, et al. Plasma leptin level is associated with cardiac autonomic dysfunction in patients with type 2 diabetes: HSCAA study. Cardiovasc Diabetol. 2015;14:117.
29. Svensson MK, Lindmark S, Wiklund U, Rask P, Karlsson M, Myrin J, Kullberg J, Johansson L, Eriksson JW. Alterations in heart rate variability during everyday life are linked to insulin resistance. A role of dominating sympathetic over parasympathetic nerve activity? Cardiovasc Diabetol. 2016;15:91.
30. Jun JE, Jin SM, Baek J, Oh S, Hur KY, Lee MS, Lee MK, Kim JH. The association between glycemic variability and diabetic cardiovascular autonomic neuropathy in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:70.
31. Shimabukuro M, Higa M, Yamakawa K, Masuzaki H, Sata M. Miglitol, α-glycosidase inhibitor, reduces visceral fat accumulation and cardiovascular risk factors in subjects with the metabolic syndrome: a randomized comparable study. Int J Cardiol. 2013;167:2108-13.